Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06029426 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
A Phase 3 study, sponsored by Neumora Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 383
- Enrollment target
NCT06029426 is a Phase 3 study that has completed, run by Neumora Therapeutics. The registered enrollment target is 383 participants.
The verdict
NCT06029426, a Phase 3 study, has completed, sponsored by Neumora Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 383 participants
- Enrollment target
Study Summary
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA-335140 501).
Interventions
- DRUG Placebo
- DRUG NMRA-335140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06029426
The ClinicalTrials.gov registry entry for NCT06029426 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neumora Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06029426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06029426 about?
NCT06029426 is a clinical study titled "Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder". This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treat...
What is the current status of trial NCT06029426?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 383 participants. The study started on 2023-09-20. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT06029426?
The interventions under investigation include: Placebo (DRUG), NMRA-335140 (DRUG).
Who is sponsoring clinical trial NCT06029426?
This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.